Suppr超能文献

类固醇诱导性骨质疏松症的治疗有哪些新进展?

What is new in the treatment of steroid-induced osteoporosis?

作者信息

Liu Rosemarie H, Werth Victoria P

机构信息

Department of Internal Medicine, Yale-New Haven Hospital, New Haven, CT, USA.

出版信息

Semin Cutan Med Surg. 2006 Jun;25(2):72-8. doi: 10.1016/j.sder.2006.04.003.

Abstract

Glucocorticoid-induced osteoporosis (GIOP) is a serious complication resulting from long-term steroid treatment. In addition to several nonpharmacologic therapies recommended by the American College of Rheumatology, various pharmacologic therapies, such as calcium, vitamin D, hormone-replacement therapy, calcitonin, and bisphosphonates, can be used to prevent and/or treat GIOP. Bisphosphonates, which are potent inhibitors of bone resorption, are considered the most effective and first-line agents for increasing bone mineral density and decreasing the risk of fracture. Human parathyroid hormone has emerged as a promising agent for the treatment of severe GIOP when used alone or in combination with a bisphosphonate.

摘要

糖皮质激素性骨质疏松症(GIOP)是长期使用类固醇治疗导致的一种严重并发症。除了美国风湿病学会推荐的几种非药物疗法外,各种药物疗法,如钙、维生素D、激素替代疗法、降钙素和双膦酸盐,可用于预防和/或治疗GIOP。双膦酸盐是骨吸收的强效抑制剂,被认为是增加骨密度和降低骨折风险最有效且一线的药物。单独使用或与双膦酸盐联合使用时,人甲状旁腺激素已成为治疗严重GIOP的一种有前景的药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验